Alector, Inc. (ALEC): restructuring charge — Alector AL002 Phase 2 fails primary endpoint; cuts workforce 17%

Alector, Inc.

AL002 did not slow Alzheimer's progression on CDR-SB; no benefit on secondary endpoints or biomarkers.
Stopping long-term extension of INVOKE-2 study; reducing workforce by ~41 employees (17% of staff).
Restructuring charges estimated at $3.9 million, primarily severance and benefits, to be paid by H1 2025.
Cash and investments of $457.2M as of Sep 30, 2024 expected to fund operations through 2026.
Topline data for latozinemab Phase 3 in FTD-GRN expected late 2025/early 2026; AL101/GSK4527226 Phase 2 enrollment over one-third.

item 2.05 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Alector, Inc. announced a restructuring with charges of approximately $3.9 million (approximately 41 employees).

Type: restructuring
Charge: approximately $3.9 million
Headcount: approximately 41 employees

Exact text from the filing

On November 25, 2024, Alector, Inc. (“Alector” or “the Company”) committed to a plan to reduce its workforce (the “Plan”) by approximately 17% in order to align resources with the Company's strategic priorities. Based upon the results of the Company's INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in early Alzheimer’s disease, the Company is stopping the long term extension of the INVOKE-2 study. The Company initiated a reduction in force impacting approximately 41 employees across the organization. The Company continues to expect that its existing cash, cash equivalents and investments will enable it to fund its operating expenses and capital expenditure requirements through 2026. One-time restructuring charges associated with the reduction in force are expected to be approximately $3.9 million, primarily consisting of personnel expenses such as salaries, one-time severance payments, and other benefits.

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Alector, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-130564

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.